ストックスクリーナーアプリを入手
0.4457
4.91%
-0.023
Gt Biopharma Inc (GTBP) 最新ニュース
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward Guidance Trends - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickNew Listing Stocks - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
GT Biopharma Q1 2026 Earnings: Wider-than-Expected Loss Amid Continued DevelopmentProfit Cycle Analysis - newsline.com
GT Biopharma, Inc. 8-K Filing: Nasdaq Compliance, Company Details & Key Disclosures (May 20, 2026) 10 - Minichart
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price By Investing.com - Investing.com South Africa
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price - Investing.com
GT Biopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq grants GT Biopharma (NASDAQ: GTBP) 180-day minimum bid reprieve - Stock Titan
GT Biopharma Edges Higher, Testing Key Resistance at $0.45Community Watchlist Picks - Newser
GT Biopharma Q1 2026 Earnings: Wider-Than-Expected Loss Amid Strategic Pipeline UpdatesEarnings Power Value - Newser
GT Biopharma Inc stock (US36254L1098): new B7-H3 TriKE enters the clinic and puts NK cell engagers i - AD HOC NEWS
Exclusive: GT Biopharma begins testing of lead solid tumor drug candidate across multiple cancer types - MSN
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic - Sahm
Why Is GT Biopharma, Inc. (GTBP.PA) Stock Down Today? - Meyka
GT Biopharma Inc stock (US36254L1098): clinical pipeline and stock under pressure after recent finan - AD HOC NEWS
Key facts: GT Biopharma Q1 Loss $2.83M; Nasdaq Listing at Risk - TradingView
GT Biopharma, Inc. Q1 2026 Financial Results: Quarterly Report, Financial Statements, and Key Disclosures - Minichart
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GT Biopharma Reports First Quarter 2026 Financial Results - The Manila Times
GT Biopharma, Inc. 1Q 2026: Net loss $(2.83M), Revenue $0— 10-Q Summary - TradingView
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] GT Biopharma, Inc. Quarterly Earnings Report - Stock Titan
GTBP Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors - Baystreet.ca
GT Biopharma stock (US36254L1098): First patient dosed in solid tumor trial - AD HOC NEWS
GT Biopharma Inc - Menafn.com
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - Toronto Star
GT Biopharma doses first patient in solid tumor trial By Investing.com - Investing.com South Africa
GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors - marketscreener.com
GT Biopharma doses first patient in solid tumor trial - Investing.com India
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):